Remote spatiotemporally controlled and biologically selective permeabilization of blood-brain barrier.

The blood-brain barrier (BBB), comprised of brain endothelial cells with tight junctions (TJ) between them, regulates the extravasation of molecules and cells into and out of the central nervous system (CNS). Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of a broad range of brain disorders. Current strategies for BBB opening are invasive, not specific, and lack precise control over the site and timing of BBB opening, which may limit their clinical translation. In the present report, we describe a novel approach based on a combination of stem cell delivery, heat-inducible gene expression and mild heating with high-intensity focused ultrasound (HIFU) under MRI guidance to remotely permeabilize BBB. The permeabilization of the BBB will be controlled with, and limited to where selected pro-inflammatory factors will be secreted secondary to HIFU activation, which is in the vicinity of the engineered stem cells and consequently both the primary and secondary disease foci. This therapeutic platform thus represents a non-invasive way for BBB opening with unprecedented spatiotemporal precision, and if properly and specifically modified, can be clinically translated to facilitate delivery of different diagnostic and therapeutic agents which can have great impact in treatment of various disease processes in the central nervous system.

[1]  R. Edwards Drug delivery via the blood–brain barrier , 2001, Nature Neuroscience.

[2]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[3]  V. Šubr,et al.  Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Libutti,et al.  Pulsed-High Intensity Focused Ultrasound and Low Temperature–Sensitive Liposomes for Enhanced Targeted Drug Delivery and Antitumor Effect , 2007, Clinical Cancer Research.

[5]  J. Karp,et al.  Mesenchymal stem cell therapy: Two steps forward, one step back. , 2010, Trends in molecular medicine.

[6]  K. Hynynen,et al.  MRI-guided disruption of the blood-brain barrier using transcranial focused ultrasound in a rat model. , 2012, Journal of Visualized Experiments.

[7]  C. Moonen,et al.  Spatial and temporal control of expression of therapeutic genes using heat shock protein promoters. , 2005, Methods.

[8]  Jeremy P. Sauer,et al.  Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles , 2014, Nature Medicine.

[9]  S. Guccione,et al.  Use of in vivo bioluminescence and MRI to determine hyperthermia‐induced changes in luciferase activity under the control of an hsp70 promoter , 2012, NMR in biomedicine.

[10]  B. Cornelissen,et al.  Selective Permeabilization of the Blood–Brain Barrier at Sites of Metastasis , 2013, Journal of the National Cancer Institute.

[11]  H. Lei,et al.  Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis , 2001 .

[12]  Kullervo Hynynen,et al.  Ultrasound enhanced drug delivery to the brain and central nervous system , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[13]  M. Prados,et al.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. , 2003, Neuro-oncology.

[14]  M. Kerin,et al.  Advances in mesenchymal stem cell-mediated gene therapy for cancer , 2010, Stem Cell Research & Therapy.

[15]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[16]  A. Bahrami,et al.  Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy , 2015, Cell biology international.

[17]  Mehmet Fatih Yanik,et al.  mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. , 2013, Blood.

[18]  Charles A. Gersbach,et al.  Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors , 2012, Journal of the American Chemical Society.

[19]  E. Neuwelt,et al.  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.

[20]  S. Kang,et al.  Journey of Mesenchymal Stem Cells for Homing: Strategies to Enhance Efficacy and Safety of Stem Cell Therapy , 2012, Stem cells international.

[21]  F. Lejeune,et al.  High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. , 1995, European journal of cancer.

[22]  D. Robertson,et al.  Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  Kenneth R Diller,et al.  Stress protein expression kinetics. , 2006, Annual review of biomedical engineering.

[24]  K. Shah Mesenchymal stem cells engineered for cancer therapy. , 2012, Advanced drug delivery reviews.

[25]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[26]  R M Henkelman,et al.  Ex vivo tissue‐type independence in proton‐resonance frequency shift MR thermometry , 1998, Magnetic resonance in medicine.

[27]  J. de Vellis,et al.  Stem cell‐based cell therapy in neurological diseases: A review , 2009, Journal of neuroscience research.

[28]  M. Fukui,et al.  Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. , 1996, Neurosurgery.

[29]  Weian Zhao,et al.  Mesenchymal Stem Cell Biodistribution, Migration, and Homing In Vivo , 2014, Stem cells international.

[30]  S. Rapoport Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy , 2001, Expert opinion on investigational drugs.

[31]  C. Moonen,et al.  Image-guided, noninvasive, spatiotemporal control of gene expression , 2009, Proceedings of the National Academy of Sciences.

[32]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[33]  F. Jolesz,et al.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences. , 2014, Neurologic clinics.

[34]  K. Hynynen,et al.  Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. , 2012, Neurosurgical focus.

[35]  F. Balkwill Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[36]  M. Andreeff,et al.  Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging , 2009, Stem cells.

[37]  P. Black,et al.  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Bynoe,et al.  Adenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier , 2011, The Journal of Neuroscience.

[39]  D. Fortin,et al.  Recent Advances in Blood–Brain Barrier Disruption as a CNS Delivery Strategy , 2008, The AAPS Journal.

[40]  S. Rapoport,et al.  Tight‐Junctional Modification as the Basis of Osmotic Opening of the Blood‐Brain Barrier a , 1986, Annals of the New York Academy of Sciences.

[41]  K. Hynynen,et al.  Trans-skull ultrasound therapy: the feasibility of using image-derived skull thickness information to correct the phase distortion , 1999, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[42]  J. Segovia,et al.  Transmigration of Neural Stem Cells across the Blood Brain Barrier Induced by Glioma Cells , 2013, PloS one.

[43]  Jeffrey M Karp,et al.  Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.

[44]  Kullervo Hynynen,et al.  Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.

[45]  C. Moonen,et al.  Combination of cell delivery and thermoinducible transcription for in vivo spatiotemporal control of gene expression: a feasibility study. , 2011, Radiology.

[46]  K. Hynynen,et al.  MRI investigation of the threshold for thermally induced blood–brain barrier disruption and brain tissue damage in the rabbit brain , 2004, Magnetic resonance in medicine.

[47]  G. Daley,et al.  The promise of induced pluripotent stem cells in research and therapy , 2012, Nature.

[48]  A. Di Stefano,et al.  Designing prodrugs for the treatment of Parkinson's disease , 2012, Expert opinion on drug discovery.

[49]  Randall J. Platt,et al.  Optical Control of Mammalian Endogenous Transcription and Epigenetic States , 2013, Nature.

[50]  S. Gambardella,et al.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. , 2010, International journal of clinical and experimental medicine.

[51]  S. Maier,et al.  MAGNETIC RESONANCE IMAGING‐GUIDED, HIGH‐INTENSITY FOCUSED ULTRASOUND FOR BRAIN TUMOR THERAPY , 2006, Neurosurgery.

[52]  Z. Qin,et al.  Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. , 1999, Brain research. Molecular brain research.

[53]  Thomas Knobloch,et al.  Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB) , 2011, Journal of drug targeting.

[54]  X. Wu,et al.  Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.